New Fully Absorbable Percutaneous Vascular Closure Device Approved in EU

Vivasure Medical, a company based out of Ireland, has received CE Mark for its fully absorbable percutaneous vascular closure device for use in large vessel femoral arteriotomies following transcatheter procedures.

Vascular closure devices are used to attain hemostasis of the small hole in the artery after a cardiovascular procedure of endovascular surgery requiring a catheterization.

New Endovascular Treatment is More Effective For Patients With Stroke
It is performed by inserting a thin tube into the artery in the groin, through the body and into the brain vessels to the clot.

‘New fully absorbable percutaneous vascular closure device from Vivasure Medical is capable of addressing fairly large arterial cuts.’

Tweet it Now

The Vivasure is capable of addressing fairly large arterial cuts developed when delivering transcatheter heart valves and conducting endovascular abdominal aortic aneurysm repairs.

The Vivasure device is sutureless, bioabsorbable while being synthetic in nature, improves post op healing, and supposedly saves time in the cath lab.

Cardiovascular diseases are disorders of the heart and blood vessels. They include cerebrovascular disease, coronary heart disease, rheumatic heart disease and other conditions.

Four out of five CVD deaths are due to strokes and heart attacks.

The field of endovascular surgery came from interventional radiology techniques to treat disease that is endovascular. Basic procedure involve the introduction of a catheter percutaneously into a large blood vessel by Seldinger technique.

Minimally Invasive Aortic Aneurysm Repair Shows Promise
A minimally invasive approach appears safe for treating life-threatening aneurysms that occur in the deepest part of the aorta, making it easier for surgeons to repair the aorta without opening the chest and easier for patients to recover.

Source-Medindia

Endovascular Treatment Should Still be an Option for Some Stroke Patients: Study
Endovascular treatment is still a reasonable treatment option for selected patients with acute stroke, despite recent discouraging results, according to a commentary.